Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | BCHE | P06276 | 3/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092685 | 1.00 | KMT2A (0.62) | KMT2AMEN1BCHEADRB2SMN1; SMN2 | |
| SCHEMBL6095014 | 1.00 | KMT2A (0.62) | KMT2AMEN1BCHEADRB2SMN1; SMN2 | |
| SCHEMBL6094415 | 0.91 | L3MBTL1 (0.55) | KMT2AMEN1BCHEADRB2SMN1; SMN2 | |
| SCHEMBL6272264 | 0.91 | L3MBTL1 (0.55) | KMT2AMEN1BCHEADRB2SMN1; SMN2 | |
| SCHEMBL6094413 | 0.91 | L3MBTL1 (0.55) | KMT2AMEN1BCHEADRB2SMN1; SMN2 | |
| SCHEMBL6093321 | 0.88 | OPRK1 (0.62) | KMT2AMEN1BCHESMN1; SMN2LMNA | |
| SCHEMBL6093314 | 0.88 | OPRK1 (0.62) | KMT2AMEN1BCHESMN1; SMN2LMNA | |
| SCHEMBL6095459 | 0.86 | MEN1 (0.60) | KMT2AMEN1ADRB2MAPTKDM4E | |
| SCHEMBL6093797 | 0.86 | KMT2A (0.59) | KMT2AMEN1SMN1; SMN2HTTLMNA | |
| SCHEMBL6094349 | 0.86 | ADRB2 (0.74) | KMT2AMEN1ADRB2SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | disclosed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-27 | — | — | US | disclosed |
| EP-1440052-A1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037847-A1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | KMT2A 793/4885MEN1 2183/4885BCHE 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.